Counterfeit and substandard drug risk: what the record shows

Counterfeit and substandard medication is a documented danger, and it does not affect every drug or every channel equally. This page lays out what federal and clinical sources actually establish — how risk concentrates by drug class, by distribution channel, and by source country — without either understating the danger or inflating it beyond what the evidence supports.

What the measurement record establishes — and its limits

The most-cited global figure comes from the World Health Organization, which estimates that at least 1 in 10 medical products in low- and middle-income countries is substandard or falsified.[1] Two limits matter and the WHO states them itself. First, the estimate covers low- and middle-income countries, not U.S. personal-import shipments specifically. Second, it covers medicines broadly — the underlying data skews toward antimalarials and antibiotics sampled in particular regions — not all prescription drugs from all sources. The WHO has been explicit that these are approximations made in the absence of reliable comprehensive data.[1] Peer-reviewed systematic reviews in the same setting have estimated a comparable-to-somewhat-higher overall prevalence, on the order of 13–14 percent.[2] What none of these figures provides is a reliable counterfeit rate for medication mailed to a U.S. patient from a specific foreign source; the data to compute that does not exist in the public record.

For the domestic baseline, the FDA’s position is that the regulated U.S. supply chain is among the safest in the world — and, as the companion page on source verification details, that the agency has no oversight of medicine from outside that chain.[3] The distance between those two statements is the entire subject of this page.

Why risk concentrates: drug class

Counterfeiting follows economics. Three structural features make a drug class a more attractive target. Unit price: high-cost specialty drugs offer more margin per faked unit. Supply constraint and demand pressure: shortages and surging demand pull buyers toward unofficial channels, which is where falsified product circulates. Detection difficulty: an end user cannot readily judge the contents of an injectable or a reconstituted biologic the way they might notice an obviously wrong tablet. These factors explain why the documented cases cluster where they do.

High-priced specialty and injectable drugs

Falsified versions of expensive injectable and specialty drugs have repeatedly reached patients. The FDA documented counterfeit cancer drug (Avastin) reaching U.S. medical practices in 2012, and has issued repeated alerts about counterfeit and unauthorized versions of the GLP-1 drug semaglutide (Ozempic) in recent years.[4][5] One distinction must be stated plainly, because it cuts against an easy reading: these were largely infiltrations of the U.S. domestic supply chain through unlicensed wholesalers and unauthorized distributors — not personal-import cases. Their relevance here is by drug-class characteristic, not by channel: they show that high-price, high-demand injectable and specialty products are precisely the targets counterfeiters pursue, which bears on the risk profile of importing those same classes through unverified channels.

Controlled substances and pills resembling prescription opioids

The gravest documented harm involves counterfeit pills made to look like prescription medications. The DEA reports that illicitly manufactured fentanyl is mass-pressed into fake pills resembling oxycodone, hydrocodone, and alprazolam, and that these pills are often lethal.[6] The DEA’s laboratory lethality figure has moved over time: roughly 4 in 10 fentanyl-containing fake pills carried a potentially lethal dose in 2021, rising to about 6 in 10 in 2022 and 7 in 10 in 2023, and most recently reported at about 5 in 10 (2 in every 5) in 2024.[6][7] In 2025 the DEA seized more than 47 million fentanyl-laced counterfeit pills.[7] Federal documentation links this directly to online ordering: the DEA has described a case in which a U.S. patient who ordered what was sold as oxycodone from an illegal online pharmacy received a fentanyl-laced counterfeit and died of acute fentanyl poisoning, with India and the Dominican Republic identified among source countries for such operations.[8] Controlled substances fall outside this site’s scope (see controlled substances), but they are the clearest illustration of how lethal a counterfeit pill channel can be.

Other targeted classes

Federal enforcement operations have intercepted counterfeit and unapproved versions across a wide range — including erectile-dysfunction drugs, hormone products, and others — routed through international mail. FDA-led international operations have repeatedly found that packages marketed as originating in one country actually contained product sourced from elsewhere.[9]

Why the channel matters more than the flag

Across the federal record, the most consistent predictor of counterfeit risk is not the country named on the package — it is the distribution channel. Enforcement operations have repeatedly documented product marketed as coming from Australia, the U.K., New Zealand, or Canada that was in fact sourced from other countries entirely.[9] A “source country” printed on a label is a marketing claim, not a chain of custody. The channel features that recur in higher-risk cases are concrete: no valid prescription required, prices far below market, payment in unusual forms, informal or social-media sales, and no verifiable chain of custody. This is why the source-verification page concludes that the consumer-visible signals fail: they describe the flag, not the channel.

This page provides general information drawn from federal, clinical, and peer-reviewed sources. It is not medical advice or legal advice, and it cannot assess any individual product. Consult a licensed prescriber or pharmacist about your medication and a U.S.-licensed attorney about your circumstances.